Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
|CytRx Corporation Reports Second Quarter...||08/09/19|
|Licensee Orphazyme A/S Rapidly Completes Enrollment in Clinical Trials for Multiple Indications and Prepares for Regulatory Submissions LOS ANGELES , ...|
|Date||04/12/2019 (AMC)||Est. (EPS/Rev.)||$1.37|
|Actual (EPS/Rev.)||$2.5B||EPS (TTM)||$???|